Natural killer cell-derived extracellular vesicles (NK-EVs) hold promising potential as cancer biotherapeutics. This methodology-based study presents a scalable closed-loop biomanufacturing workflow designed to continuously produce and isolate large quantities of high-purity NK-EVs. In-process control testing is performed throughout the biomanufacturing workflow, ensuring the EVs meet quality standards for product release.
Natural killer cell-derived extracellular vesicles (NK-EVs) are being investigated as cancer biotherapeutics. They possess unique properties as cytotoxic nanovesicles targeting cancer cells and as immunomodulatory communicators. A scalable biomanufacturing workflow enables the production of large quantities of high-purity NK-EVs to meet the pre-clinical and clinical demands. The workflow employs a closed-loop hollow-fiber bioreactor, enabling continuous production of NK-EVs from the NK92-MI cell line under serum-free, xeno-free, feeder-free, and antibiotic-free conditions in compliance with Good Manufacturing Practices standards. This protocol-driven study outlines the biomanufacturing workflow for isolating NK-EVs using size-exclusion chromatography, ultrafiltration, and filter-based sterilization. Essential NK-EV product characterization is performed via nanoparticle tracking analysis, and their functionality is assessed through a validated cell viability-based potency assay against cancer cells. This scalable biomanufacturing process holds significant potential to advance the clinical translation of NK-EV-based cancer biotherapeutics by adhering to best practices and ensuring reproducibility.
In the 21st century, remarkable advancements have been achieved in the battle against cancer. This is mainly due to the rise of cancer immunotherapeutics, a class of drugs that harnesses the immune system to fight cancer. Natural killer cell-derived extracellular vesicles (NK-EVs) represent promising contenders in the expanding realm of immunotherapy. Integrative to innate and adaptive immunity, NK cells play a crucial role in the body's defense against virus-infected, stressed, and malignant cells. They employ a comprehensive arsenal of anti-cancer machinery to eliminate abnormal cells through cytotoxic means1,2,3. Among these mechanisms is the production and secretion of EVs, nanoscale bilayer structures containing various biomolecules, such as proteins, RNAs, and DNAs, crucial for facilitating intercellular communication4,5,6. NK-EVs emerge as promising cell-free therapeutics due to their unique carrier properties. These include their small size, allowing filter-based sterilization, high biocompatibility, preferential accumulation within tumors, broad cargo delivery spectrum, capacity to overcome biological barriers such as the blood-brain barrier, and minimal toxicity profile. For several reasons, NK-EVs obviate the need for patient lymphodepletion via chemotherapy before administration: 1) conventionally, lymphodepletion is employed to create a more hospitable environment for cell-based therapy, enabling infused cells to proliferate and exert their therapeutic effects; 2) unlike cells, EVs lack the replication capacity and are substantially smaller in scale; 3) EVs operate through distinct mechanisms and exhibit diminished immunogenicity compared to cells5,6,7. Furthermore, NK-EVs consistently exhibited in vitro efficacy against various cancer models and have also shown immunomodulatory effects on immune cells that foster anti-cancer responses8,9. In vivo results corroborate these findings, showcasing cancer regression following NK-EV treatment and negligible toxicities10,11,12. Therefore, NK-EV-based therapeutics hold great promise to address the challenges of treating cold, immunologically inert solid tumors13,14,15,16,17.
Our recent study addresses a significant bottleneck to the clinical translation of NK-EVs through biomanufacturing7. The article presents a proof-of-concept for a cost-effective and scalable biomanufacturing workflow of NK-EVs meticulously designed to ensure in-process quality control testing. This approach continuously produced large quantities of high-purity NK-EV-based cancer biotherapeutics, with thorough product characterization conducted according to the MISEV2018 guidelines18. The scalability of the biomanufacturing workflow can be achieved by increasing cartridge size or having multiple bioreactors running in parallel. Similarly, the scalability of the EV isolation workflow can be easily attainable using techniques like Fast Protein Liquid Chromatography (FPLC) based size-exclusion chromatography (SEC), ultrafiltration (UF), and filter-based sterilization. The closed-loop hollow-fiber bioreactor (HFB) system grew the IL-2-self-sufficient NK cell line (NK92-MI cells) without requiring serum supplementation, a feeder system, and antibiotics. This was accomplished using a commercially available chemically defined and xeno-free medium (a GMP version is now commercially available). As a result, large quantities of NK cells (109 viable cells) and NK-EVs (1012 EVs) were successfully produced within 5 – 7 days using a single medium-size bioreactor cartridge, with both products extensively characterized. Throughout the biomanufacturing process, cell health was monitored daily using quantifiable metrics such as pH, glucose, and lactate levels, along with visual indicators such as media color and any sign of contamination, which are essential predictors of cell and EV quality. Post-harvest evaluation of NK cell viability and functionality generated in the HFB system, particularly cytotoxicity, revealed a significant enhancement compared to flask-based cultures7. Likewise, purified NK-EVs exhibited a high purity profile, devoid of bacteria, mycoplasma, common viral entities, and cellular components, and with negligible endotoxin levels. Importantly, purified NK-EVs constituted over 99.9% of all nanoparticles found in the final product7. Lastly, these purified NK-EVs retained key NK characteristics, including surface markers (CD2, CD45, CD56), cytokine payload (GzmB, PFN, IFN-g), and demonstrated potent cytotoxicity against leukemic K562 cells, the gold-standard line for assessing NK cell cytotoxicity7.
The present protocol details the scalable biomanufacturing workflow discussed above. It elucidates the methodology for isolating NK-EVs produced using FPLC-SEC coupled with UF and filter-based sterilization. Additionally, the protocol describes pivotal steps, including product characterization using nanoparticle tracking analysis (NTA), quality assessment using various tools (protein/dsDNA quantification and microbial testing), and functional validation of the purified NK-EV product against cancer cells by cell viability assay. Typically, this workflow yields 1.0 – 1.5 mL of NK-EV product with an average concentration of 1.18 x 1012 EVs/mL7, totaling a minimum of 1 x 1012 EVs based on approximately 40 mL of EV-rich CM. This process allows product release for various downstream applications, such as investigatory, preclinical, and multi-omics (proteomics, transcriptomics, genomics, metabolomics, lipidomics, and epigenomics) studies demanding high quantities of high-quality EVs while holding potential for clinical translation, with demonstrated reproducibility.
Several studies suggest that NK-EVs possess vast potential as an anti-cancer therapeutic4,5,7,9,16,22,23,24,25,26,27,28,29,30. However, a scalable GMP-compliant biomanufacturing system capable of yielding large quantities of high-purity NK-EVs is required for further pre-clinical testing and future clinical applications. To address this issue, a previous study used a closed-looped HFB system to continuously produce NK cells and NK-EV-rich CM suitable for downstream experimentation. Due to their 3D design, HFB systems closely reflect the conditions of the vascular system and possess an incredibly high surface-area-to-volume ratio, permitting upwards of a billion cells to remain in culture, ultimately leading to improved EV production7,31,32. Importantly, this work was the first to ever report using an HFB system for culturing NK cells, likely due to the cell line IL-2 self-sufficiency7.
Additional steps must be taken to ensure the sterility of the HFB system and the production of high-purity NK-EVs. These precautions are especially crucial in the absence of a sterile, clean room, which may be the case for several research facilities. Before entering the biosafety cabinet, the HFB system is meticulously sprayed with 70% ethanol to disinfect all external surfaces. Additionally, wax film is wrapped around all Luer Lock connections to minimize the risk of contamination. This is particularly important as this biomanufacturing workflow does not use antibiotics, which are known to affect the biochemical profile of cell and cell-derived products33. Various metrics were used to assess cell health during cell product biomanufacturing. For example, daily assessments of the reservoir media's pH, glucose, and lactate levels were conducted as these are vital cell health surrogates for monitoring. In addition to quantitative assessments, qualitative observations of the HFB system (e.g., media color and visual signs of contamination such as turbidity) are also helpful for monitoring cell health. Cell counts on daily retrieved CM have not been found to be a representative metric of viability for the health of the culture (data not shown). This is likely a result of dead cells retrieved during CM sampling that were found within the tubing where media was not allowed to circulate (the small section between the ECS and the ECS syringe port), thereby undervaluing the viability of the overall cell culture. Only harvested NK cells produced by the HFB at the end of a production lot can provide a reliable metric of the culture's health. These cells consistently showed viability values above 70% across production lots7. Together, these quality assessment methods ensure the continuous production of high-purity NK-EVs.
Several isolation techniques have been developed to purify and isolate EVs34. One method, SEC, utilizes a column packed with a porous material – resin – allowing for molecule separation based on size discrimination. Here, the larger EVs are eluted through the column faster; this method is known as flow-through purification based on size exclusion. At the same time, smaller contaminants (dsDNA, free-floating proteins like endonuclease, salts, phenol red, etc.) are left behind and further retained within the resin by electrostatic forces (i.e., a bimodal resin was used). SEC-based processing removes non-EV-bound proteins while maintaining the original EV structure and functionality35,36. Furthermore, SEC-based purification is easily scalable without compromising the high yield and purity, making it a suitable choice for isolating NK-EVs for biotherapeutic uses. Despite these advantages, SEC has some drawbacks, such as the relatively diluted flow-through (eluent); hence, UF is required for product concentration, but it also permits buffer exchange. The non-sterile UF apparatus is rinsed with 70% ethanol and PBS and kept in the biosafety cabinet prior to use to ensure sterility. Typically, the flow-through can be concentrated to 35x-50x of the initial volume while removing small molecules that could have made their way into the eluent. Differential centrifugation and endonuclease treatment are performed before FPLC-SEC coupled with UF to remove residual cells, cellular debris, and long strands of antigenic dsDNA7.
Following NK-EV product isolation, characterization, and functional validation are performed per the guidelines in MISEV2018 and MISEV2023 to determine the product's suitability for further use6,18. Each isolation yields 1.0 – 1.5 mL of high-purity NK-EV product at a minimum concentration of 1 x 1012 EVs/mL, with an average concentration of 1.39 x 1012 particles/mL. Previously, Gupta et al. determined that the median EV dosage in vivo is 3.37 x 108 EVs/kg of body weight of mice37. Treating with the median dosage would require 8.43 x 106 EVs/mouse with a body weight of 25 g, a value far below the guaranteed minimum (1 x 1012 particles/mL) obtained through this workflow. Thus, the described biomanufacturing workflow can produce more than enough NK-EVs for pre-clinical experimentation or to meet dosing targets. Each isolation is tested for mycoplasma and microbial presence as part of the product's quality control assessment. In addition, a previous study demonstrated the absence of common viral entities and endotoxin in the final product and the absence of cellular components considered host cell contaminants (by western blot analysis)7,34. Lastly, functional assessment was performed using a validated highly sensitive resazurin-based cell viability assay to assess the NK-EVs' functionality20. The described viability assay functions by reducing resazurin (weakly fluorescent) to resorufin (highly fluorescent) by metabolically active cells, allowing for the assessment of cell viability following NK-EV treatment. Compared to other alternative cell viability assays, the resazurin-based assay used in the study is highly sensitive to changes in cell viability (very low background noise) and allows for shortened incubation time to observe results (less than 30 min to obtain statistically significant results)20. Generally, the NK-EVs exhibit a dose-dependent effect upon K562 viability. Together, the results presented represent an NK-EV product that has met the product release criteria for pre-clinical evaluation and is suitable for downstream applications.
In conclusion, this protocol-based study describes the biomanufacturing of NK-EVs with clinical-grade potential. As discussed, the NK-EVs are produced using a closed-loop HFB system under serum-free, xeno-free, feeder-free, and antibiotic-free conditions7. A combination of FPLC-SEC/UF isolates and purifies the NK-EV product. Before releasing the products for downstream application, the NK-EVs must be characterized and functionally validated to ensure they are suitable for use. As demonstrated, following this biomanufacturing protocol can successfully generate a large quantity of high-purity NK-EVs that exhibit on-target cytotoxicity against cancer cells. Therefore, the described biomanufacturing protocol may be an asset for future studies that require the production of clinical-grade NK-EVs.
The authors have nothing to disclose.
The authors would like to acknowledge Drs. Simon Sauvé, Roger Tam and Xu Zhang for their critical manuscript review. This work was supported by operating grants from the Genomics Research and Development Initiative (GRDI) Phase VII (2019-2025) from the Government of Canada obtained by JRL, LW, as well as operating grants from the Natural Sciences and Engineering Research Council RGPIN-2019-05220, Cancer Research Society/University of Ottawa 24064, the Canadian Institutes of Health (CIHR) Research Operating Grant 175177 obtained by LW, the CIHR MSc Scholarship obtained by MK, and the Queen Elizabeth II Scholarships in Science and Technology (QEII-GSST) obtained by FSDB.
0.1 µm vacuum filtration unit Filtropur V50 | Sarstedt | 83,3941,002 | |
0.22 µm Acrodisc Syringe Filter | Pall Corporation | PN4612 | |
1 mL syringe | Thermo Fisher Scientific | MB9204560TF-LAB | |
10 kDa Centricon Plus-70 Centrifugal Filter | Sigma | UFC701008 | |
60 mL syringe | BD Biosciences | 309653 | |
96-well Flat Clear Bottom Black Polystyrene TC-treated Microplates | Costar | 3603 | |
Agarose | Thermo Fisher Scientific | R0491 | |
AKTA Fast Protein Liquid Chromatograph | GE Lifesciences | 29022094 | |
BD PrecisionGlide Needle – 18G | BD Biosciences | 305196 | |
Benzonase Nuclease | Sigma | E1014-25KU | |
BioTek Synergy H1 Multimode Reader | BioTek | SH1M2G-SN | |
Blue Juice Gel Loading Buffer | Invitrogen | 10816015 | |
CaptoCore 700 resin | Cytiva | 17548102 | |
Cellometer Auto 2000 Viability Counter | Nexcelom BioScience LLC | ||
CryoStor CS10 freezing medium | Sigma | C2874 | |
DPBS−/− | Fisher | BP399-1 | |
Dual LED Blue/White Light Transilluminator | Invitrogen | LB0100 | |
Duet P3202 Flow Control Pump | FiberCell Systems | ||
Dulbecco's phosphate-buffered saline | Gibco | 14190250 | |
Ethanol | Commercial Alcohols | P006EAAN | |
Exosome-Depleted FBS | Gibco | A2720803 | |
Fluorobrite DMEM | Gibco | A18967-01 | |
Glucose meter | AccuCheck | Model 930 | |
HiScale chromatography column 10/40 | Cytiva | 29360550 | |
ImmunoCult-XF (GMP medium alternative) | StemCell Technologies | 100-0956 | |
ImmunoCult-XF T Cell Expansion Medium | StemCell Technologies | 10981 | |
Isopropyl Alcohol | EMD | PX1834-1 | |
K562 cells | ATCC | CCL-243 | |
LB media | BioBasic | SD7002 | |
L-Lactate Assay Kit | Abcam | ab65331 | |
Medium hollow-fibre cartridge | FiberCell Systems | C2011 | |
MgCl2 | Sigma | M1028 | |
Mycoplasma PCR detection kit | Abcam | ab289834 | |
NanoSight NS300 | Malvern | ||
NaOH | Supelco | SX0607N-6 | |
NK92-MI cells | ATCC | CRL-2408 | |
pH Strips-Mquant | Sigma | 1,09533 | |
PrestoBlue HS Cell Viability Reagent Assay | Invitrogen | P50200 | |
Qubit 4 Fluorometer | Invitrogen | ||
Qubit dsDNA BR Assay Kit | Invitrogen | Q33262 | |
Qubit dsDNA HS Assay Kit | Invitrogen | Q33231 | |
Qubit Flex Assay Tube Strips | Invitrogen | Q33252 | |
Qubit Flex Fluorometer | Invitrogen | Q33327 | |
Qubit Protein BR Assay Kit | Invitrogen | A50669 | |
Quick Load 1Kb Plus DNA ladder | NEB | N0469S | |
SYBRSafe DNA Gel Stain Invitrogen | Invitrogen | S33102 | |
Syringe pump | Harvard Apparatus | 984730 | |
Triton-X 100 | Sigma | T-9284 | |
UltraPure TAE Buffer | Invitrogen | 15558042 | |
ViaStain Acridine Orange and Propidium Iodide (AO/PI) Staining Solution | ESBE Scientific | CS2-0106 |
.